PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.
The addition of apatinib to gefitinib prolonged PFS compared with gefitinib among treatment-naive patients with EGFR-mutated NSCLC.
The use of modern postoperative conformal radiotherapy did not improve DFS and was associated with toxicities among patients with stage IIIAN2 NSCLC.
NGS of longitudinal samples from patients with advanced NSCLC receiving ICIs identified changes associated with hyperprogression and early death.
Results from a phase 1 trial suggest a KRASG12C inhibitor has a favorable safety profile and antitumor activity in advanced NSCLC.
An analysis of from the Flatiron Health Network found that some patients with NSCLC with a KRASG12C mutation do not receive systemic therapy.